Background: C-reactive protein (CRP) is an essential biomarker for evaluating penile cancer prognosis. Previous studies have reported conflicting outcomes concerning the correlation between CRP levels and penile cancer prognosis. This study aimed to investigate this relationship by conducting a meta-analysis of published literature.
Methods: A systematic literature search was conducted using the Cochrane Library, PubMed, and Embase databases to analyze the prognostic significance of serum CRP levels in individuals diagnosed with penile cancer. Pooled risk estimates were calculated using fixed-effects or random-effects models, depending on the degree of interstudy heterogeneity.
Results: Sixty-eight articles were reviewed, identifying 8 articles and 989 patients that met the inclusion criteria for the meta-analysis. The pooled analysis revealed a significant association between serum CRP levels and adverse outcomes in penile cancer cases (hazard ratio [HR] = 2.37, 95% confidence interval [CI] = 1.46-3.858). Additional meta-analysis findings showed a negative correlation between elevated CRP levels and overall survival (HR = 1.97, 95% CI = 1.23-3.16, p<0.01), cancer-specific survival (HR = 3.42, 95% CI = 1.38-8.47, p<0.01), and disease-specific survival (HR = 3.23, 95% CI = 1.79-5.8, p<0.01) in patients with penile cancer. In the subgroup analysis, the HRs (95% CI) were 1.66 (0.61-4.48) in Europeans, 3.08 (2-4.74) in Asians, 3.04 (1.93-4. 77) in Chinese, 2.07 (1.21-3.53) in the group of cutoff value ≥ 5 mg/L, 2.43 (1.44-4.12) in the group of cutoff value ≥ 10 mg/L, 2.12 (1.04-4.32) in the group of surgical intervention, and 3.07 (1.76-5.37) in the group of multitherapy. This study also found a significant relationship between serum CRP levels and lymph node metastasis in patients with penile cancer (relative risk = 2.27, 95% CI = 1.61-3.2, p<0.01).
Conclusion: This meta-analysis indicates that increased CRP levels were associated with a poorer prognosis in penile cancer. Therefore, CRP levels could potentially serve as a prognostic indicator of penile cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889917 | PMC |
| http://dx.doi.org/10.1186/s12957-025-03664-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Role Of DSNB in Staging of Primary Urethral Cancer: New Standard?
Int Braz J Urol
March 2025
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
We describe the novel use of dynamic sentinel node biopsy (DSNB) in five patients with primary urethral squamous cell carcinoma (U-SCC) and no evidence of inguinal node disease across two centers in North America and Europe between 03/2021 and 06/2024. Each of these referral centers sees over 75 cases of penile cancer per year and approximately 10 cases of U-SCC per year. Patients underwent DSNB concomitant to surgical resection of the primary tumor (n=3), or in a deferred manner (n=2), six weeks after primary surgery.
View Article and Find Full Text PDFImmunotherapy in the Management of Penile Cancer-A Systematic Review.
Cancers (Basel)
March 2025
Divison of Oncology, Karl Landsteiner University of Health Sciences, 3500 Krems, Austria.
Penile cancer, though a rare malignancy, presents a significant challenge in the domain of male genitourinary oncology, particularly due to its limited treatment options and due to the profound physical and psychological impact on patients [...
View Article and Find Full Text PDFEfficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis.
Exp Hematol Oncol
March 2025
The University of Kansas Cancer Center, 2650 Shawnee Mission Pkwy, Westwood, KS, 66205, United States of America.
Penile squamous cell carcinoma (PSCC) is a rare malignancy, and first-line therapy typically involves cisplatin-based chemotherapy. However, these regimens are often unsuitable for patients with poor performance status or advanced age due to their toxicity. This retrospective, multicenter study evaluated patients with metastatic PSCC who received immune checkpoint inhibitor (ICI) therapy between 2017 and 2024.
View Article and Find Full Text PDFPenile prosthesis for erectile dysfunction: recommendations from the 5th International Consultation on Sexual Medicine.
Sex Med Rev
March 2025
Department of Urology, University of Texas MD Anderson Cancer Center and McGovern Medical School at Houston, Houston, 77030, TX, United States.
Introduction: Penile prosthesis (PP) is one of the main approved therapies for erectile dysfunction (ED). Greater than 50 years of clinical use has led to considerable innovation in PP surgery and patient care.
Objectives: To summarize the current literature and provide updated clinical evidence to inform healthcare providers on best practices with PP.
A patient with penile metastasis secondary to small cell lung cancer successfully treated with PD-1 inhibitors and chemotherapy: a case report and literature review.
Front Oncol
February 2025
Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: Penile metastasis is an uncommon condition, with most primary malignancies originating in the abdominal cavity and pelvis. There have been very few reported cases originating from lung cancer, most of squamous cell carcinoma without small cell lung cancer.
Methods: We presented a case of penile metastasis secondary to small cell lung cancer, along with a review of relevant literature from the CNKI database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!